Comparison of serum soluble edoglin (sEng) level in eary onset preeclampsia, late onset preeclampsia and normal pregnant woman
Downloads
Objectives: This study aimed to compare the serum levels of soluble Endoglin (s-Eng) between early onset preeclampsia, late onset preeclampsia and normal pregnant women.
Materials and Methods: This was an analytic observational study (Cross-Sectional) performed on 39 pregnant women with early-onset preeclampsia (EO-PE), late-onset preeclampsia (LO-PE), and normal pregnancy. The patients were consecutively chosen in Dr. Soetomo Hospital, Airlangga University Hospital and Dr. M. Soewandhi Hospital Surabaya in May-July 2016. The serum concentration of soluble Endoglin were collected by venous puncture taken from maternal circulation and measured by ELISA.
Results: From this study, serum concentrations of soluble Endoglin was higher significantly on the early onset preeclampsia compared with late onset preeclampsia and normal pregnancy (47,65 ± 40,17 vs 13,46 ± 9,48 vs 6,11 ± 1,45 ng/mL; p=0.000). Conclusion: This study shows angiogenic imbalance was more prominent compared in early-onset than late-onset preeclampsia. This may be because the placental dysfunction, placental ischemia, which produce excessive anti angiogenic factors, whic later causing endothelial dysfunction was more related to early onset preeclampsia.Perez L Lopez-Novoa JM. Soluble endoglin: a bio-marker or a protagonist in the pathogenesis of preeclampsia. Port J. Nephrol Hypert. 2014;28(3): 185-192
Lam C, Lim KH, Karumanchi SA. Circulating an-giogenic factors in the pathogenesis and predic-tion of preeclampsia. Hypertension 2005;46: 1077-1085.
Jerkic M, Rivas-Elena J, Santibanez J, et al. Endo-glin regulates cyclooxygenase-2 expression and activity. Circ. Res. 2006;99;248-56.
Ahmed A, Wenda R. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm? British Journal of Pharmacology. 2014;172:1574-86.
Whitman M, Raftery L. TGF-ï¢ signaling at The Summit. Development 2005;132:4205-10.
Levine RJ, Lam C, Qian C, Yuet al. Soluble endoglin and other circulating antiangiogenic fac-tors in preeclampsia. N Engl J Med. 2006; 355:992-1005
Omar SZ, Qvist R et al. Angiogenic factors in the pathogenesis and pathophysiology of Preeclampsia: A mini review. Biomedical Research 2010; 21(3); 246 – 251.
Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of pre-eclampsia. Nature Medicine 2006;12(6):642-50.
Sibai BM. Biomarker for hypertension-preeclamp-sia. Are we close yet ? AJOG 2007;1-2.
Dekker G, Sibai BM. Primary, secondary, and tertiary prevention of preeclampsia. Lancet 2001; 357:209-15
Lamminpaa R, Julkunen KV, Gissler M, Heinonen S. Preeklampsia complicated by advnanced mater-nal age: a registry-based study on primiparous women in Finland 1997-2008. BMC Pregnancy and Childbirth 2012;12(47):
Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies : Prospective cohort study. BMJ 2009;18(338): b2255.
Baeten JM, Bukusi EA, Lambe M. Pegnancy com-plications and outcomes among overweight and obese nulliparaous women. American Journal of Public Health 2001;91(3):
Karumanchi SA, Naljayan MV. New developments in the pathogenesis of preeclampsia. Published as : Adv. Chronic Kidney Dis. HHMI Howard Hughes Medical Institute. PubMed Central 2013;20(3): 265-70.
Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. Medical Principl-es and Practice 2013;22(Suppl.1):8-19.
Rana R, Karumanchi SA, Levine RJ, et al. Sequen-tial changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137-42.
Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endo-glin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. The J of Clin Endocrin & Metab. 2007; 92(7): 2672–79.
Wikstrom AK, Larsson A, Eriksson UJ et al. Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 in Early-Onset Preeclampsia. Am J Obstetricians Gynecologists 2007; 109(6) :138-1374
Maynard SE, Moore Simas TA, Bur L et al. Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertension in Pregnancy 2010; 29(3):330-41.
Karumanchi SA, Lindheimer MD. Preeclampsia pathogenesis: "Triple A Rating" autoantibodies and antiangiogenic factors. Hypertension 2008;51:991-2.
Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. Journal of Pregnancy 2012.
Dadelszen PV, Magee LA, Roberts JM. Sub-classification of preeclampsia. Hypertens Pregnan-cy 2003;22:143-148
Weiler J, Tong S, Palmer KR, Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. PLoS ONE 2011;6:e26937.
Herraiz I, Simon E, Gomez-Arriaga PI, et al. Angiogenesis-related biomarkers (sFlt-1/PlGF) in the prediction and diagnosis of placental dys-function: An approach for clinical integration. Int J Mol Sci. 2015;16:19009-26; doi: 10.3390/ijms 160819009
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
